ArticleNature2024
Cellular adaptation to cancer therapy along a resistance continuum.
Abstract read
In one paragraph
Article in Nature, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers.
0numbers the graph read from it
0cells of the map it votes in
129citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed.
- Multi-omics analysis reveals the attenuation of the interferon pathway as a driver of chemo-refractory ovarian cancer.Cell reports. Medicine · 2025Trial
- Neoadjuvant fuzuloparib combined with abiraterone for localized high-risk prostate cancer (FAST-PC): A single-arm phase 2 study.Cell reports. Medicine · 2025Trial
- Bis-(di-4-phenyl-benzylaminethiocarbonyl)disulfide sensitizes ABCC2/ALDH3A1 overexpressing NSCLC cells to cisplatin.Cancer biology & therapy · 2026Article
- Advancing antibody drug conjugates in gastrointestinal cancers.British journal of cancer · 2026Review
- CCT2 enhances c-Myc stabilization to drive tumor progression and chemoresistance in head and neck squamous cell carcinoma.Genes & diseases · 2026Article
- Reframing cancer therapy through tumor plasticity.Nature cancer · 2026Review
- Mechanistic modeling reveals a configurable AP-1 network governing cell-state heterogeneity and adaptive plasticity in melanoma cells.Cell reports · 2026Article
- Rethinking Drug Resistance in Acute Promyelocytic Leukemia: The Regulated Cell Death Network as an Integrative Framework.Biomolecules · 2026Review
- Dissecting residual disease in spheroids reveals pan-cancer persistence signatures and a therapeutic window for oncolytic viruses.Molecular therapy. Oncology · 2026Article
- Drugging small-molecule compounds in autophagy-dependent cell death to overcome cancer therapy resistance.Apoptosis : an international journal on programmed cell death · 2026Review
- Spatiotemporal lineage tracing reveals the dynamic spatial architecture of tumor growth and metastasis.Nature genetics · 2026Article
- Targeting PRMT5 Inhibitor-Induced Adaptation in Pancreatic Cancer with the RBM39 Degrader Indisulam.Cancer research communications · 2026Article
- URMylation Signaling Pathway in Cancer: Molecular Mechanisms and Therapeutic Opportunities.Current issues in molecular biology · 2026Review
- A Non-Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non-Small Cell Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Bioinformatic characterization of SLC25A39 across cancers with validation in hepatocellular carcinoma.Discover oncology · 2026Article
- Molecular Characterization of PARP Inhibitor Response Reveals Co-Targeting Strategies in Advanced Prostate Cancer.Cancers · 2026Article
- Pre-Existing Heterogeneity Predicts Rare Proteostasis-Stress Programs Across Diverse Perturbations.Biology · 2026Article
- Single-cell multimodal profiling of pan-cancer cell lines uncovers gene regulatory principles underlying intrinsic cell states and environmental features.Nature communications · 2026Article
- Concurrent genetic and non-genetic resistance mechanisms to KRAS inhibition in colorectal cancer.Cancer cell · 2026Article
- Paclitaxel in oncology: balancing anticancer efficacy with potential carcinogenic risks and resistance mechanisms.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Gustavo S FrançaInstitute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Maayan Baron *Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Benjamin R King *Institute for Systems Genetics, NYU Grossman School of Medicine, New York, NY, USA.
Jozef P Bossowski *Department of Pathology, NYU Grossman School of Medicine, New York, NY, USA.
Alicia Bjornberg *Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0002-9683-4071
Maayan Pour *Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Anjali Rao *Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0001-8815-9865
Ayushi S Patel *Institute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Selim MisirliogluLaura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, USA.
Dalia BarkleyInstitute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0001-6537-5557
Kwan Ho TangLaura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0001-7729-5159
Igor DolgalevApplied Bioinformatics Laboratories, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-4451-126X
Deborah A LibermanInstitute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-5029-0611
Gal AvitalInstitute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Felicia KuperwaserInstitute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Marta ChiodinInstitute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA.
Douglas A LevineLaura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, USA.
Thales PapagiannakopoulosLaura and Isaac Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-2251-1624
Andriy MarusykDepartment of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.ORCID 0000-0002-0087-9575
Timothée LionnetInstitute for Systems Genetics, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0003-1508-0202
Itai YanaiInstitute for Computational Medicine, NYU Grossman School of Medicine, New York, NY, USA. itai.yanai@nyulangone.org.ORCID 0000-0002-8438-2741
Funding
Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OSMAN, IMAN · 2019 to 2025
$12.5MProject 3: The Evolving Role of Regional Lymph Nodes in Melanoma ProgressionU54CA263001 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Kelly Valentine Ruggles · 2022 to 2026
$11.6MThe Delta Ecology of NSCLC TreatmentU54CA274507 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI Alexander Robertson Allan Anderson, ROBERT A GATENBY · 2023 to 2026
$9.4MIdentifying metabolic dependencies in genetic subtypes of KRAS-driven lung cancerR37CA222504 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAPAGIANNAKOPOULOS, THALES · 2018 to 2024
$3.3MDissecting CEBPB Function with Synthetic Biology and ImagingR01AG075272 · NIA · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Timothee Lionnet · 2022 to 2026
$3.2MIdentification and characterization of cancer cell states by novel computational and experimental technologies - Resubmission - 1U01CA260432 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Richard Mark White, ITAI YANAI · 2022 to 2026
$2.9MUncovering Genotype Specific Vulnerabilities in KRAS Mutant Lung Cancer?R01CA227649 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI PAPAGIANNAKOPOULOS, THALES · 2018 to 2022
$1.9MComputational approaches for the systematic detection of cell-cell interactions by spatial transcriptomics - Resubmission - 1R01LM013522 · NLM · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI YANAI, ITAI · 2021 to 2024
$1.4MInferring cell state tumor microenvironment maps by integrating single-cell and spatial transcriptomicsR21CA264361 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI YANAI, ITAI · 2021 to 2022
$516kSpatially resolved single-cell patterns of drug-resistant ovarian cancersF32CA239394 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI KING, BENJAMIN ROBERT · 2019 to 2021
$156kCancer cell state interactions with immune populations of the tumor microenvironmentF30CA257400 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BARKLEY, DALIA · 2021 to 2023
$135kNCI NIH HHS F30 CA257400NCI NIH HHS F32 CA239394NCI NIH HHS P50 CA225450NCI NIH HHS R01 CA227649NCI NIH HHS R21 CA264361NCI NIH HHS R37 CA222504NCI NIH HHS U01 CA260432NCI NIH HHS U54 CA263001NCI NIH HHS U54 CA274507NIA NIH HHS R01 AG075272NLM NIH HHS R01 LM013522
Abstract
Advancements in precision oncology over the past decades have led to new therapeutic interventions, but the efficacy of such treatments is generally limited by an adaptive process that fosters drug resistance
Indexed as
Adaptation, PhysiologicalCell PlasticityDrug Resistance, NeoplasmNeoplasmsAnimalsCell Line, TumorCellular ReprogrammingEpigenesis, GeneticEpithelial-Mesenchymal TransitionFemaleGene Expression Regulation, NeoplasticHumansMicePhenotype
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.